HangZhou Fanttest Biotech Co,. Ltd.
HangZhou Fanttest Biotech Co,. Ltd.

Insulin-like Growth Factor-binding Protein 1 (iGFBP-1) Rapid Test

Contact Us
IFU
Background Intended Use Operation

iGFBP-1 Rapid Test Product Background

Insulin – like growth factor – binding protein 1 (iGFBP – 1) known as placental protein 12 (PP12) is a protein that in humans is encoded by the IGFBP1 gene. IGF – binding proteins (iGFBPs) is believed to be important in the regulation of fetal and neonatal growth. We previously reported that the profifiles of iGFBPs in fetal cord serum (FCS) were dependent on the growth/metabolic status of the fetus. It can be detected in cervical secretions of pregnant women with preterm uterine c ontractions, and whether their presence predicts an increased risk of preterm delivery. The abundance of insulin – like growth factor binding protein -1 at the maternal-fetal interface in severely preeclamptic pregnancies suggests that the binding protein may participate in the pathogenesis of the shallow placental invasion observed in this disorder. Low circulating insulin – like growth factor – I and elevated insulin-like growth factor binding protein – 1 levels may contri bute to restricted placental and therefore fetal growth.

View More View Less

iGFBP-1 Rapid Test Intended Use

The Insulin – like Growth Factor – binding Protein 1 (iGFBP – 1) Rapid Test is a rapid qualitative immunochromatographic test for the detection of phosphorylated iGFBP – 1 (insulin – like growth factor binding protein – 1) in cervical secretions during pregnancy

View More View Less

iGFBP-1 Rapid Test Operation Steps And Result Interpretation

igfbp-1-rapid-test-operation.png


  • POSITIVE: * Two lines appear. One colored line should be in the control line region (C) and another apparent colored line should be in the test line region (T).

    *NOTE: The intensity of the color in the test line region (T) will vary depending on the concentration of IGFBP-1 present in the specimen. Therefore, any shade of color in the test line region (T) should be considered positive.

  • NEGATIVE: One colored line appears in the control line region (C). No line appears in the test line region (T).

  • INVALID: Control line fails to appear. I nsuffiffifficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the procedure and repeat the test with a new test. If the problem persists, discontinue using the test kit immediately and contact your local distributor.


View More View Less
Please Contact Us
Please Contact Us

To monitor your health status anytime, anywhere and achieve self-inspection and self-testing.

07/28
2026
Invitation: International Medical Device Exhibition & Conference 2026
Date: 26–28 August 2026Venue: Kuala Lumpur Convention Center, Kuala Lumpur, MalaysiaBooth No: H4 . 4078Fanttest cordially invites global distributors, healthcare professionals, and industry partners ...
07/24
2026
Fanttest’s 2026 exhibition at the Queen Sirikit National Convention Center (QSNCC) in Bangkok successfully concluded on July 10
Fanttest’s 2026 exhibition at the Queen Sirikit National Convention Center (QSNCC) in Bangkok successfully concluded on July 10. Over the three-day event at Booth J.28, we had the opportunity to conn...
07/02
2026
Invitation: World Health Expo 2026
Date: 08–10 July 2026Venue: Queen Sirikit National Convention Center (QSNCC), Bangkok, ThailandBooth No: J.28Fanttest cordially invites global distributors, healthcare professionals, and industry par...